Reconciliation of Stockholders' (Deficit) Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Deficit Attributable to Internat'l Isotopes Shareholders	Equity Attributable to Noncontrolling Interest	Total
Beginning balance, value at Dec. 31, 2018	$ 4,131,683	$ 120,805,997	$ (126,541,421)	$ (1,603,741)	$ 1,757,875	$ 154,134
Beginning balance, shares at Dec. 31, 2018	413,168,301
Shares issued under employee stock purchase plan, value	$ 316	1,265		1,581		1,581
Shares issued under employee stock purchase plan, shares	31,618
Stock grant, value	$ 2,798	(2,798)
Stock grant, shares	279,767
Stock in lieu of dividends on convertible preferred C shares, value	$ 34,330	171,650		205,980		205,980
Stock in lieu of dividends on convertible preferred C shares, shares	3,433,000
Stock based compensation		63,737		63,737		63,737
Net (loss) income			(51,958)	(51,958)	108,492	56,534
Ending balance, value at Mar. 31, 2019	$ 4,169,127	121,039,851	(126,593,379)	(1,384,401)	1,866,367	481,966
Ending balance, shares at Mar. 31, 2019	416,912,686
Beginning balance, value at Dec. 31, 2019	$ 4,198,423	121,680,163	(128,064,385)	(2,185,799)	2,073,649	(112,150)
Beginning balance, shares at Dec. 31, 2019	419,842,256
Shares issued under employee stock purchase plan, value	$ 1,568	5,098		6,666		6,666
Shares issued under employee stock purchase plan, shares	156,845
Stock grant, value	$ 3,021	(3,021)
Stock grant, shares	302,125
Stock in lieu of dividends on convertible preferred C shares, value	$ 34,080	170,400		204,480		204,480
Stock in lieu of dividends on convertible preferred C shares, shares	3,408,000
Convertible debenture beneficial conversion feature		102,584		102,584		102,584
Warrants issued with convertible debentures		144,976		144,976		144,976
Stock based compensation		51,522		51,522		51,522
Net (loss) income			(422,494)	(422,494)	44,457	(378,037)
Ending balance, value at Mar. 31, 2020	$ 4,237,092	$ 122,151,722	$ (128,486,879)	$ (2,098,065)	$ 2,118,106	$ 20,041
Ending balance, shares at Mar. 31, 2020	423,709,226